Page last updated: 2024-11-11

nb 598

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NB 598: decreases serum total & LDL-cholesterol levels; structure given in first source; inhibits squalene epoxidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6443223
CHEMBL ID27885
SCHEMBL ID9454490
SCHEMBL ID9454494
MeSH IDM0181400

Synonyms (31)

Synonym
[3-([3,3'']bithiophenyl-5-ylmethoxy)-benzyl]-((e)-6,6-dimethyl-hept-2-en-4-ynyl)-ethyl-amine
bdbm50032850
gtpl3103
[(2e)-6,6-dimethylhept-2-en-4-yn-1-yl](ethyl)[(3-{[4-(thiophen-3-yl)thiophen-2-yl]methoxy}phenyl)methyl]amine
nb-598 ,
NCGC00165845-01
nb 598
CHEMBL27885 ,
SCHEMBL9454490
SCHEMBL9454494
HY-16343
CS-1274
131060-14-5
benzenemethanamine, 3-((3,3'-bithiophen)-5-ylmethoxy)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-ethyl-, (e)-
n-ethyl-n-(6,6-dimethyl-2-hepten-4-ynyl)-3-((3,3'-bithiophen-5-yl)methoxy)benzenemethanamine
(e)-3-[(3,3'-bithiophen)-5-ylmethoxy]-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-ethylbenzylamine
EX-A1748
(e)-n-(3-(3,3'-bithiophen-5-ylmethoxy)benzyl)-n-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine
(e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-ethyl-3-[4-(3-thienyl)-2-thienylmethyoxy]benzylamine
KIRGLCXNEVICOG-SOFGYWHQSA-N
(e)-n-(3-([3,3'-bithiophen]-5-ylmethoxy)benzyl)-n-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine ,
Q27087856
nb 598; nb598
BCP28146
A14131
EMV ,
(2e)-n-({3-[([3,3'-bithiophen]-5-yl)methoxy]phenyl}methyl)-n-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine
benzenemethanamine, 3-([3,3'-bithiophen]-5-ylmethoxy)-n-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-ethyl-
D83658
A937201
AS-79002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID204662Compound was evaluated in vivo for the inhibition of rat mammalian squalene epoxidase in HepG2 cells1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
Sulfonamide derivatives of benzylamine block cholesterol biosynthesis in HepG2 cells: a new type of potent squalene epoxidase inhibitors.
AID204661In vitro inhibitory activity against pig liver microsomal squalene epoxidase1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
(Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors.
AID60301Compound was evaluated for plasma concentration in dog 1 hr after at a dose of 10 mg/kg2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID170077Compound was evaluated for area under the curve (0-8 h)2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID176793In vivo ability to inhibit cholesterol biosynthesis from [14C]acetate after a single oral administration in female rats1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
(Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors.
AID86224In vitro ability to inhibit cholesterol biosynthesis in HepG2 cells in culture from [14C]mevalonate1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
(Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors.
AID190808Compound was evaluated for maximum time(Tmax) in suspension of 0.5% methylcellulose at a dose of 10 mg/kg in rat2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID173102Compound was evaluated for maximum concentration (Cmax) in suspension of 0.5% methylcellulose at a dose of 10 mg/kg in rat2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID89405In vitro inhibitory activity was evaluated against human squalence epoxidase2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID60307Compound was evaluated for plasma concentration in dog 4 hr after at a dose of 10 mg/kg2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID179765In vitro inhibitory activity was evaluated against rat squalence epoxidase2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID172655Bioavailability in rat2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID60304Compound was evaluated for plasma concentration in dog 24 hr after at a dose of 10 mg/kg2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID86222In vitro ability to inhibit cholesterol biosynthesis in HepG2 cells in culture from [14C]acetate1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
(Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors.
AID59347In vitro inhibitory activity was evaluated against dog squalence epoxidase2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID16452Partition coefficient (logP)2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
AID1346881Human squalene synthase (Lanosterol biosynthesis pathway)1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
(Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's18 (66.67)18.2507
2000's6 (22.22)29.6817
2010's1 (3.70)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.75 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index28.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]